Compare MAN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | VCEL |
|---|---|---|
| Founded | 1948 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 1994 | 1996 |
| Metric | MAN | VCEL |
|---|---|---|
| Price | $33.72 | $44.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $35.67 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 1.1M | 724.5K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $17,957,100,000.00 | $276,259,000.00 |
| Revenue This Year | $5.12 | $19.40 |
| Revenue Next Year | $3.42 | $18.24 |
| P/E Ratio | $675.40 | ★ N/A |
| Revenue Growth | 0.58 | ★ 16.45 |
| 52 Week Low | $25.15 | $28.95 |
| 52 Week High | $47.34 | $46.62 |
| Indicator | MAN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 73.47 |
| Support Level | $28.29 | $32.47 |
| Resistance Level | $36.87 | N/A |
| Average True Range (ATR) | 1.64 | 1.73 |
| MACD | 0.04 | 0.68 |
| Stochastic Oscillator | 38.49 | 80.63 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.